Celularity (NASDAQ:CELU) Raised to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen has upgraded Celularity (NASDAQ:CELU) to a "sell" rating, suggesting a bearish outlook for the stock.
• Celularity reported a net loss of ($0.59) earnings per share but exceeded analysts' expectations for revenue with $18.13 million, compared to a forecast of $5.20 million.
• The company's stock has fluctuated between a 12-month low of $1.00 and a high of $5.22, currently trading at around $3.12.

Celularity (NASDAQ:CELU - Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a "sell" rating in a report released on Saturday.

Celularity Stock Performance

NASDAQ:CELU traded up $0.04 during mid-day trading on Friday, hitting $3.16. The stock had a trading volume of 114,452 shares, compared to its average volume of 179,070. The company has a current ratio of 0.38, a quick ratio of 0.28 and a debt-to-equity ratio of 4.07. The company has a 50 day simple moving average of $2.30 and a 200-day simple moving average of $1.96. The stock has a market capitalization of $75.68 million, a price-to-earnings ratio of -1.19 and a beta of 0.79. Celularity has a 52 week low of $1.00 and a 52 week high of $5.22.

Celularity (NASDAQ:CELU - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($1.50) by $0.91. Celularity had a negative net margin of 106.77% and a negative return on equity of 271.88%. The company had revenue of $18.13 million for the quarter, compared to the consensus estimate of $5.20 million.

Institutional Investors Weigh In On Celularity

A number of large investors have recently made changes to their positions in the company. Valmark Advisers Inc. acquired a new stake in shares of Celularity during the second quarter valued at approximately $98,000. Acadian Asset Management LLC acquired a new position in Celularity in the 1st quarter valued at approximately $34,000. Finally, Two Sigma Investments LP acquired a new position in Celularity in the 4th quarter valued at approximately $93,000. Institutional investors and hedge funds own 19.02% of the company's stock.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.